856 related articles for article (PubMed ID: 2548711)
21. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000.
Lehmann JM; Holzmann B; Breitbart EW; Schmiegelow P; Riethmüller G; Johnson JP
Cancer Res; 1987 Feb; 47(3):841-5. PubMed ID: 3542195
[TBL] [Abstract][Full Text] [Related]
22. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
24. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
25. MACG1, a mouse monoclonal antibody detecting a monosialoganglioside expressed in tumor-infiltrating macrophages.
Schriever F; Dennis RD; Riethmüller G; Johnson JP
Cancer Res; 1988 May; 48(9):2524-30. PubMed ID: 3356014
[TBL] [Abstract][Full Text] [Related]
26. TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.
Lyle S; Salhany KE; Elder DE
Mod Pathol; 2000 Jan; 13(1):52-5. PubMed ID: 10658910
[TBL] [Abstract][Full Text] [Related]
27. Mouse monoclonal antibody (FKH1) detecting human melanoma-associated antigens.
Fukaya T; Hashimoto K; Eto H; Mehregan A
Cancer Res; 1986 Oct; 46(10):5195-200. PubMed ID: 3756874
[TBL] [Abstract][Full Text] [Related]
28. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3.
Werkmeister JA; Triglia T; Mackay IR; Dowling JP; Varigos GA; Morstyn G; Burns GF
Cancer Res; 1987 Jan; 47(1):225-30. PubMed ID: 3791209
[TBL] [Abstract][Full Text] [Related]
29. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.
Albelda SM; Mette SA; Elder DE; Stewart R; Damjanovich L; Herlyn M; Buck CA
Cancer Res; 1990 Oct; 50(20):6757-64. PubMed ID: 2208139
[TBL] [Abstract][Full Text] [Related]
30. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G
Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
32. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
33. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
34. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
35. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
36. [Mouse monoclonal antibody (FKH1) detecting human melanoma-associated antigens: production, partial characterization and immunohistochemical analysis].
Fukaya T
Hokkaido Igaku Zasshi; 1991 May; 66(3):300-10. PubMed ID: 1885156
[TBL] [Abstract][Full Text] [Related]
37. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype.
Bani MR; Rak J; Adachi D; Wiltshire R; Trent JM; Kerbel RS; Ben-David Y
Cancer Res; 1996 Jul; 56(13):3075-86. PubMed ID: 8674065
[TBL] [Abstract][Full Text] [Related]
38. Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture.
Herlyn M; Rodeck U; Mancianti M; Cardillo FM; Lang A; Ross AH; Jambrosic J; Koprowski H
Cancer Res; 1987 Jun; 47(12):3057-61. PubMed ID: 3034401
[TBL] [Abstract][Full Text] [Related]
39. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
Steuhl KP; Rohrbach JM; Knorr M
Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
[TBL] [Abstract][Full Text] [Related]
40. Histopathological characteristics of malignant melanoma affecting mucous membranes: a unifying concept of histogenesis.
Saida T; Kawachi S; Takata M; Kurita H; Kurashina K; Kageshita T; Tonogi M; Okazaki Y; Yamane GY; Takubo K; Ueyama Y
Pathology; 2004 Oct; 36(5):404-13. PubMed ID: 15370109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
